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Mathematical modelling of the restenosis process after stent
implantation
Javier Escuer1 · Miguel A. Martı´nez1,2 · Sean
McGinty3 · Estefanı´a Pen˜a1,2
Abstract The stenting procedure has evolved to become a highly successful technique
for the clinical treatment of advanced atherosclerotic lesions in arteries. However, the
development of in-stent restenosis remains a key problem. In this work, a novel 2D con-
tinuum mathematical model is proposed to describe the complex restenosis process fol-
lowing the insertion of a stent into a coronary artery. The biological species considered to
play a key role in restenosis development are growth factors, matrix metalloproteinases,
extracellular matrix, smooth muscle cells and endothelial cells. Diffusion-reaction equa-
tions are utilized for modelling the mass balance between species in the arterial wall. Ex-
perimental data from the literature have been used in order to estimate model parameters.
Moreover, a sensitivity analysis has been performed to study the impact of varying the
parameters of the model on the evolution of the biological species. The results demon-
strate that this computational model qualitatively captures the key characteristics of the
lesion growth and the healing process within an artery subjected to non-physiological
mechanical forces. Our results suggest that the arterial wall response is driven by the
damage area, smooth muscle cells proliferation and the collagen turnover among other
factors.
Keywords: restenosis, stent, ISR, coronary artery, diffusion-reaction equations, contin-
uum models.
1 Introduction
Cardiovascular diseases (CVDs) are the leading cause of mortality in the world. In Eu-
rope, 3.9 million deaths a year are attributed to CVDs, with coronary heart disease
(CHD) and stroke the primary culprits [1]. CHD is characterized by the development
of atherosclerotic plaque, consisting of deposits of cholesterol and other lipids, calcium
and macrophages, within the arterial wall. This causes a progressive reduction in the lu-
men available for the blood flow (stenosis), hardening and loss of elasticity of the arterial
tissue.
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2The use of endovascular devices such as stents and balloons to treat advanced atheroscle-
rotic lesions is now commonplace in the clinic. However, one of the major limitations of
these interventions is the development of restenosis [2–7]. Restenosis is understood to
comprise of three main mechanisms: elastic recoil (in the short term), vessel remodelling
and neointimal hyperplasia (in the longer term). The first and second mechanisms are
typical in the case of balloon angioplasty, whereas stent deployment usually promotes
the formation of neointimal hyperplasia, associated with smooth muscle cell (SMC)
migration and proliferation and extracellular matrix (ECM) deposition [7]. Coronary
revascularization now generally involves the use of a stent in more than 70% of cases,
leading to reduced restenosis rates in comparison to balloon angioplasty alone. With
the advent of drug-eluting stents (DES) the incidence of restenosis has been dramati-
cally reduced to approximately <10-12% of all angioplasties [8]. However, DES do not
completely remove this problem. Since the precise mechanisms behind restenosis after
stenting, so-called in-stent restenosis (ISR), are still not fully understood, it therefore
remains a significant clinical challenge to predict which patients will develop ISR.
Experimental studies have established a strong correlation between the level of arterial
injury caused by the device and the following neointimal thickness and lumen diameter
reduction at the stented area [9,10]. Novel stent designs and stent-deployment protocols
that minimise induced vascular injury are therefore needed. However, the optimum stent
design and the ideal drug release strategy still remain in question despite technological
advances [11].
Complementary to the wide variety of experimental studies, computational analysis has
emerged as a useful method for designing new medical devices in order to minimise
ISR. In the last two decades, many computational models of stent deployment have
been developed to study the stress-strain level that the device induces within the arterial
wall [12–15]. Several mathematical and numerical models have also been developed to
try to understand drug release from stents and subsequent redistribution in the arterial
tissue [16–20]. Less attention, however, has been directed to modelling the biological
response to treatment.
In recent years, mechanobiological models have emerged to relate mechanics to the com-
plex biological response. These have primarily made use of discrete agent based models
(ABM) or cellular automata (CA) methods, in some cases combining with finite ele-
ment analysis (FEA). For example, Zahedmanesh et al. developed an agent based model
to investigate the dynamics of the SMC in vascular tissue engineering scaffolds [21] and
an ABM of ISR which allows a quantitative evaluation of the ECM turnover after stent-
induced vascular injury [22]; Boyle et al. demonstrated that non-linear growth could be
simulated with a cell-centred model [23] and simulated ISR by modelling a combina-
tion of injury and inflammation with SMCs represented as discrete agents [24, 25] and;
Keshavarzian et al. [26] developed a mechanobiological model of arterial growth and re-
modelling. Evans et al. [27] highlighted the importance of using a multiscale approach
to describe computationally the main physical and biological processes implicated in
ISR, introducing the concept of the complex autonoma (CxA) models, based on a hi-
erarchical aggregation of coupled CA and ABM models. Tahir et al. [28] focussed on
the initial phase after stenting and developed a cellular Potts model from which they hy-
pothesized that deeper stent deployment allows easier migration of SMC into the lumen.
Most recently, Zun et al. [29] presented a 3D multiscale model of ISR with blood flow
simulations coupled to an agent-based SMC proliferation model and demonstrated qual-
itative agreement with in vivo porcine data. In the aforementioned examples, discrete
3models attempted to represent individual cells in the form of a lattice governed by a set
of rules, in contrast to the continuum approach where the evolution of populations of
cells and other species such as growth factors are described through partial differential
equations (PDEs).
In terms of continuum models, Rachev et al. [30] proposed a theoretical continuum
model to describe the main mechanisms of the coupled deformation and stress-induced
arterial tissue thickening observed at the regions close to an implanted stent, comparing
the results obtained with experimental data documented in the available literature [31].
However, this phenomenological model does not take into account, for example, the
mechanisms implicated in the SMC proliferation or the ECM synthesis. Other contin-
uum mathematical biological models typically comprise of a series of coupled diffusion-
reaction equations for describing the biological interaction between several species.
Such models have been developed to describe phenomena such as neointimal hyper-
plasia formation [32], atherosclerotic plaque formation [33–36], fibrotic tissue forma-
tion surrounding medical implants [37, 38] and more recently, in-stent restenosis [39]
and arterial physiopathology [40]. In contrast to discrete models where cell behaviour is
usually described by a set of rules, continuum models offer a mechanistic description,
featuring physical parameters which may in principle be measured. In addition, contin-
uum models often have a lower computational cost than ABM, and naturally allow for
modelling diffusion of species and coupling with the mechanical aspects of the problem.
In this paper, we develop a model that allows us to simulate the restenosis process fol-
lowing the insertion of a stent into a coronary artery. The key novelty of our model is that
it adopts a continuum approach to describe the sequence of events following damage to
the arterial wall, and is therefore formulated in terms of densities/concentrations of a
number of important species. This is advantageous because it allows us to assess how
the evolution of the various species affects the overall healing process, and more impor-
tantly, how variations in the associated parameters and initial conditions influences the
process. Diffusion-reaction equations are used for modelling the mass balance between
biological species in the arterial wall. The main species considered to play a key role
in the process are SMCs, endothelial cells (ECs), matrix-degrading metalloproteinases
(MMPs), growth factors (GFs) and ECM. The parameters used in the model to define
the biological interaction between the different species have been adapted from exper-
imental data available in the literature. Unlike any of the existing continuum models,
we are able to simulate the time-course response of six different biological species in-
volved in ISR after the initial mechanical damage, whilst at the same time simulating
tissue growth. Our primary aim is to gain insight into the physical mechanisms of tis-
sue remodelling post-stenting. Simulating patient-specific cases is beyond the scope of
this work: historically, mathematical and computational models in the stents domain
have been formulated in idealised scenarios to gain insight before moving onto more
realistic patient-specific geometries. With this in mind, we employ a simplified geom-
etry. Notwithstanding, we do compare our results to clinical data and use our model to
asses the impact of geometric variations on the final outcome through consideration of
a series of commercial stents as well as different inter-strut distances and levels of strut
embedment, thereby enabling us to relate our findings to stent design.
42 Governing equations and model assumptions
ISR is an immeasurably complex multiscale system involving a large number of species
and an intricate cascade of biological processes (Fig. 1). Indeed, much of the biology
is still unknown. Due to its complexity, in this model we include only what we be-
lieve are the predominant species and processes. Specifically, we consider three types
of cells (contractile and synthetic SMCs and ECs) and three extracellular components
(GFs, MMPs and ECM). We consider the following behaviour: cell types can prolifer-
ate, migrate, differentiate and die (apoptosis) while the extracellular components can be
produced or degraded. Since the processes considered take place predominantly in the
intima and media layers, in the following model the arterial wall refers to these layers,
with the adventitia considered as the outer boundary. Furthermore, blood flow in the lu-
men and plasma filtration in the tissue have not been included. We refer the reader to
Section 5 for a full discussion of the limitations of this work.
[Fig. 1 about here.]
2.1 Material model
An isotropic hyperelastic constitutive model based on a Yeoh strain energy function
(SEF) [41] was considered to describe the stress-strain response of the arterial wall. We
assume the same mechanical response for the intima and the media layer. Assuming
incompressibility of the tissue, the Yeoh SEF can be written as:
Ψ = c10(I1 − 3) + c20(I1 − 3)2 + c30(I1 − 3)2 (1)
where c10 = 17.01 kPa, c20 = −73.42 kPa and c30 = 414.95 kPa, are the hyperelastic
material constants and I1 is the first strain invariant of the Cauchy-Green deformation
tensor. The coefficients of the hyperelastic model were identified from fitting the ex-
perimental results obtained from Holzapfel et al. [42] in specimens of human coronary
arteries for the media layer in the circumferential direction using the software for cali-
bration of hyperelastic material models (HyperFit, www.hyperfit.wz.cz).
The stent is modelled as an elasto-plastic material with a Young’s modulus of E=200
GPa, Poisson’s ratio of ν =0.28 (representative of biomedical grade stainless steel alloy
316L) and plasticity described by isotropic hardening J2 flow theory with the tensile
stress-strain curves taken from the literature, including a yield strength of 264 MPa and a
ultimate tensile strength (UTS) of 584 MPa at an engineering plastic strain of 0.247 [15].
2.2 Initial estimation and evolution of the damage
Although not completely elucidated, the stimulus triggering the cascade of inflamma-
tory events leading to neointimal formation appears to come from the endothelial dam-
age caused immediately after balloon dilatation and stent placement [43]. We do not
explicitly account for all of the mechanical factors that initiate the process which leads
to vessel injury and endothelial dysfunction. Following Zahedmanesh et al. [22], we as-
sign a level of injury to the arterial wall, d, in a continuous range from 0 to 1. Due to
the absence of reliable mechanical data in literature on the stress-strain levels known to
5cause arterial injury, the experimental data of in vitro tensile tests up to failure of 13
human left anterior descending (LAD) coronary arteries [42] were used to obtain a qual-
itative estimation of the damage in the tissue. In particular, we define a piecewise linear
function to prescribe the initial arterial damage as a function of von Mises stress, σvm,
calculated by a FE simulation of the stent expansion:
d0 =

0 if σvm ≤ σvm,inf
σvm−σvm,inf
σvm,sup−σvm,inf if σvm,inf < σvm < σvm,sup
1 if σvm ≥ σvm,sup
(2)
where d0 is the initial damage in the tissue due to the stent placement. This function
assigns a value of zero for the damage in areas of the arterial wall in which von Mises
stress is lower than σvm,inf and a value of 1 for the damage in those regions in which
von Mises stress exceed σvm,sup (Fig. 2).
[Fig. 2 about here.]
Moreover, damage, d, is assumed to decrease continuously with time at a rate directly
proportional to the MMP concentration, cmmp [24]. The damage evolution equation is
therefore:
∂d
∂t
= −kdeg,d d cmmp︸ ︷︷ ︸
Degradation
, (3)
where d is a continuous function of space and time, d(r, z, t), to describe the damage
level, kdeg,d is the degradation rate of damage and cmmp(r, z, t) is the concentration of
MMP. Eq. 3 may be considered as a simple description of healing.
2.3 Species evolution
(a) Growth Factors (GFs):
After mechanical arterial injury, platelets, leukocytes and SMCs, among others, release
several types of GFs: platelet-derived GF (PDGF), epidermal GF (EGF), insulin-like GF
(IGF), transforming GF (TGF) and fibroblast GF (FGF) [2, 3, 5, 7]. However, since their
specific roles in the inflammatory phase are not completely understood [2], the term GF
includes the combined action of all of them. Denoting the concentration of GFs in the
arterial wall by cgf (r, z, t), and assuming an initial value of cgf,0 [44], their behaviour
is modeled as follows:
∂cgf
∂t
+∇ · (−Dgf∇cgf )︸ ︷︷ ︸
Random motion
= kprod,gf d
(
1− cgf
cgf,th
)
︸ ︷︷ ︸
Production
− kdeg,gf
(
cgf − cgf,0
)︸ ︷︷ ︸
Degradation
. (4)
We are assuming that the GFs experience random motion (i.e., diffusion). Although the
diffusion coefficient, Dgf , may in general depend on position, we take it here to be con-
stant [32]. The right hand side of Eq. 4 considers a dynamic balance between degradation
6and production. GF production is assumed to follow logistic growth: the concentration
increases proportionally to the production rate, kprod,gf , and level of damage, d, until
some threshold value, cgf,th, is reached. To simplify the mathematical model, we con-
sider that vascular damage is the only trigger of GF production. Degradation, on the
other hand, is assumed to occur at a constant rate, kdeg,gf , and in proportion to the
‘distance’ from the initial value.
(b) Matrix-degrading metalloproteinases (MMPs):
Human MMPs are a family of 26 members of zinc-dependent proteolytic enzymes which
are considered to be the normal and physiologically relevant mediators of ECM degra-
dation [45, 46]. Given that MMP-2 cleaves a wider range of ECM constituents [22],
the term MMP specifically refers to MMP-2 in this model. ECs, SMCs, fibroblasts
and infiltrating inflammatory cells are able to produce MMPs. In this work, we assume
that mechanical damage resulting from stenting upregulates MMP production only by
SMCs [46], while at the same time MMP is reduced at a constant rate [24]. The MMP
evolution equation is defined as follows:
∂cmmp
∂t
+∇ · (−Dmmp∇cmmp)︸ ︷︷ ︸
Random motion
=
(
kprod1,mmpccsmc + kprod2,mmpcssmc
)
d
(
1− cmmp
cmmp,th
)
︸ ︷︷ ︸
Production
− kdeg,mmp
(
cmmp − cmmp,0
)︸ ︷︷ ︸
Degradation
, (5)
where cmmp is the concentration of MMPs, Dmmp is the diffusion coefficient to simu-
late the random movement of MMP molecules, kprod1,mmp and kprod2,mmp are the pro-
duction rates of MMPs by contractile and synthetic SMCs, respectively, and kdeg,mmp
is the constant degradation rate of MMPs. The parameter cmmp,0 represents the initial
concentration of MMP in the tissue [47], whilst cmmp,th is the threshold MMP concen-
tration.
(c) Extracellular Matrix (ECM)
The ECM is the non-cellular component of the arterial wall that provides physical scaf-
folding for the cellular constituents and is responsible for cell-matrix interactions [48],
playing a crucial role in the development of the pathogenesis of restenosis. In particular,
ECM components are involved in the regulation of SMCs phenotype: degradation of
ECM after stenting promotes the transition of SMCs from a quiescent/contractile to an
active/synthetic phenotype, whereas its synthesis leads to the opposite [49]. In this work,
the behaviour of ECM has been directly related to the behaviour of collagen which con-
stitutes the major component of mature restenotic tissue [7]. For this reason, collagen is
assumed to be the only component of the ECM in our model. Collagen is secreted by
synthetic SMCs [2] and degraded at a rate proportional to the amount of MMPs [7, 24],
so its behaviour can be defined as follows:
7∂cecm
∂t
= kprod,ecmcssmc
(
1− cecm
cecm,th1
)
︸ ︷︷ ︸
Production
− kdeg,ecm
(
cmmp − cmmp,0
) (
1− cecm,th2
cecm
)
︸ ︷︷ ︸
Degradation
, (6)
where cecm(r, z, t) is the concentration of collagen, which is produced at a rate kprod,ecm
and degraded at a degradation rate kdeg,ecm. The initial concentration of collagen is
cecm,0 [47]. We assume that the natural synthesis of collagen is equal to the age-related
degradation rate, therefore these terms have not been taken into account in this equation.
Moreover, we assume that ECM kinetics are dominated by production and degradation
and that random motion of ECM is negligible.
(d) Contractile smooth muscle cells (cSMC)
SMCs are the most prominent cell type found in intimal hyperplasia. In our model,
SMCs can exist in one of two phenotypes: contractile or synthetic. Before stent implan-
tation, SMCs are in a quiescent/contractile phenotype (do not proliferate or synthesize
matrix) within the uninjured tissue. We can define the behaviour of the contractile SMCs
as:
∂ccsmc
∂t
= −kdiff,csmcccsmcKssmc,ecm︸ ︷︷ ︸
Differentiation
from cSMC to sSMC
+ kdiff,ssmccssmcKcsmc,ecm︸ ︷︷ ︸
Differentiation
from sSMC to cSMC
, (7)
where ccsmc(r, z, t) is the contractile SMCs concentration, kdiff,csmc is the differenta-
tion rate from contractile SMCs to synthetic SMCs, kdiff,ssmc is the differentation rate
from synthetic SMCs to contractile SMCs and KcSMC,ecm and Kssmc,ecm (Fig. 3)
are functions defined to modulate the SMCs differentiation as a function of the ECM
concentration:
Kssmc,ecm = −
(
e
−
( cecm,th
cecm
−1
)
−
∣∣∣ cecm,thcecm −1∣∣∣ − 1
)
, (8)
Kcsmc,ecm = −
(
e
−
(
cecm
cecm,th
−1
)
−
∣∣∣∣ cecmcecm,th−1
∣∣∣∣ − 1
)
. (9)
In this model, contractile SMCs may differentiate into synthetic SMCs and vice-versa.
The function Kssmc,ecm contributes to the emergence of the synthetic phenotype, so
when cecm < cecm,th the function Kssmc,ecm takes positives values, SMCs are acti-
vated and switch to a synthetic phenotype starting to migrate, proliferate and synthesize
ECM, while if cecm > cecm,th then Kssmc,ecm is equal to zero (no differentiation).
On the other hand, Kcsmc,ecm contributes to the emergence of the contractile pheno-
type, so when cecm 6 cecm,th then Kcsmc,ecm is zero and if cecm > cecm,th the
function Kcsmc,ecm takes a positive value and synthetic SMCs switch back to the con-
tractile phenotype. At the beginning of the simulation cecm = cecm,th so Kssmc,ecm
8and Kcsmc,ecm are both equal to zero. We assume that contractile SMCs are initially
present only in the media, and at a density of ccsmc,0 [50]. Random motion is not taken
into account for this cell type since contractile SMCs are considered quiescent and do not
migrate. Moreover, contractile SMCs are considered unresponsive to growth factors [2].
[Fig. 3 about here.]
(e) Synthetic smooth muscle cells (sSMC)
The synthetic SMCs evolution equation is as follows:
∂cssmc
∂t
+∇ · (−Dssmc∇cssmc)︸ ︷︷ ︸
Random motion
= kdiff,csmcccsmcKssmc,ecm︸ ︷︷ ︸
Differentiation
from cSMC to sSMC
−
− kdiff,ssmccssmcKcsmc,ecm︸ ︷︷ ︸
Differentiation
from sSMC to cSMC
+ kprolif,ssmc
(
cgf − cgf,0
)︸ ︷︷ ︸
Proliferation
− kapop,ssmccssmc︸ ︷︷ ︸
Apoptosis
,
(10)
where cssmc(r, z, t) is the synthetic SMCs concentration, Dssmc is the diffusion coeffi-
cient of synthetic SMCs in order to simulate the migration process, kprolif,ssmc is the
proliferation rate of synthetic SMCs in response to GFs and kapop,ssmc is the apoptosis
rate at which synthetic SMCs die. The initial density of synthetic SMCs in the arterial
wall, cssmc,0, is assumed to be equal to zero [38].
(f) Endothelial cells:
Along with SMCs, ECs constitute the main cell type within the vasculature. ECs per-
form a wide variety of significant functions, e.g. cell migration and proliferation, remod-
elling, apoptosis and the production of different biochemical substances [51], as well as
the control of vascular function [52]. Moreover, most of the mechanical responses to
flow in the arterial wall, such as shear stress and stretch, directly affect ECs indicat-
ing that these cells have specific mechanotransducers capable of transforming mechan-
ical forces into biological responses. A thin single layer of ECs form the endothelium,
which in normal conditions, besides being a permeability barrier between the blood flow
and the arterial wall, promotes vasodilatation and suppresses intimal hyperplasia by in-
hibiting inflammation, thrombus formation and SMCs proliferation and migration [53].
However, at sites of injury caused by the stent, the endothelium is denuded [7]. This de-
endothelization is considered to be one of the most important mechanisms contributing
to restenosis [54]. In this work, it is assumed that the endothelium is denuded between
stent struts, considering that only a small amount of cells survive in this region. The
behaviour of the ECs may be modeled as:
∂cec
∂t
+∇ · (−Dec∇cec)︸ ︷︷ ︸
Random motion
= kprolif,eccec
(
1− cec
cec,0
)
︸ ︷︷ ︸
Proliferation
, (11)
9where cec(r, z, t) is the density of the endothelial cells, Dec is the diffusion coefficient
of the ECs to simulate their migration from the lateral edge of the damage blood vessel
surface [2] and kprolif,ec is the ECs proliferation rate. ECs can exist only in the intima
or subendothelial spaces (SES). The initial concentration of ECs is assumed to be near
to zero at sites where the SES is injured and cec,0 [55] at the intact SES. In order to
ensure a tractable mathematical model, the equation which governs the behaviour of the
ECs is assumed to be independent of the rest of the presented coupled PDEs.
2.4 Tissue growth
We follow the continuum framework for growth of biological tissue developed by Garikipati
et al. [56] to describe the tissue growth that leads to restenosis. This formulation consid-
ers mass transport and mechanics coupled due to the kinematics of volumetric growth.
Accordingly, the balance of mass in the system must satisfy:
∂ρio
∂t
= Πi −∇ ·M i, (12)
where the index i is used to indicate an arbitrary species; ρio are the concentrations of the
species as mass per unit volume in the reference configuration; Πi are the sources/sinks
related to migration, proliferation, differentiation and apoptosis of the cells and synthesis
and degradation of the substances and; M i are the mass fluxes of the i arbitrary species.
The operators∇(•) and∇· (•) denote the gradient operator and the divergence of a vec-
tor in the reference configuration, respectively. The total material density of the tissue
(ρo) is the sum of all the individual species concentrations (ρio), i.e. ρo =
∑
i ρ
i
o. These
concentrations, ρio, evolve if local volumetric changes take place as a result of mass
transport and inter-conversion of species. That implies that the total density in the ref-
erence configuration, ρo, also changes with time, i.e. as species concentration increases,
the material of a species swells, and conversely, shrinks as concentration decreases [56].
Assuming that these volumetric changes are locally isotropic, we can define the follow-
ing growth deformation gradient tensor,F ig = (ρio)/(ρiorig)I, where ρ
i
orig represents the
original concentration of a species in the reference configuration and I is the isotropic
tensor of second order. Taking this into consideration, under the small strain hypothesis
we can write:
∇ · vi = ρ
i
o
ρiorig
, (13)
where v is the velocity of the material points [36]. Since the primary components of
restenotic tissue are ECs, SMCs and collagen (here represented by ECM), we neglect
volume contributions from the other species. Therefore, the isotropic growth that leads
restenosis can be finally determined as:
∇ · v = ∂∆cec
∂t
Vec +
∂∆csmc
∂t
Vsmc +
∂∆cecm
∂t
1
ρecm
, (14)
where ∆cec , ∆csmc and ∆cecm are the variations of concentrations of ECs, both con-
tractile and synthetic SMCs and ECM, respectively, with respect to the initial concen-
tration of these species before the restenosis process initiation. The parameters Vec and
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Vsmc are the volume of an EC and a SMC, respectively, and ρecm is the collagen den-
sity (Table 3). To calculate the volume of the individual cells, the shape of the ECs is
assumed to be spherical [22] and the SMC shape is assumed to be ellipsoidal or spindle-
shaped [57]. Therefore, the volume of each cell type may be estimated as follows:
Vec =
4
3
pir3ec, (15)
Vsmc =
4
3
pir2smclsmc, (16)
where rec is the typical radius of a EC, rsmc and lsmc are the typical radius and the
length of a SMC, respectively as shown in Table 3. This growth process has been defined
following the method described for the development of atherosclerotic plaque in [36]
and the fibrosis process after the implantation of an inferior vena cava filter in [38],
respectively.
3 Computational model
3.1 Model geometry
A 2D-axisymmetric geometry corresponding to an idealized representation of a straight
stented coronary artery segment is considered in all simulations (Fig. 4a). The baseline
computational geometry (Table 1) is similar to that introduced by Mongrain et al. [16],
also employed by Vairo et al. [18] and modified by Bozsak et al. [19] to study the stent
drug release and redistribution in the arterial wall. In order to be able to relate our find-
ings to stent design, we also assess the impact of geometric variations on the final out-
come. Specifically, we consider geometrical parameters for three commercial stents,
Resolute (Medtronic), Xience (Abbott Vascular) and Biomatrix (Biosensors), whose
strut dimensions were obtained from Byrne et al. [58], as well as varying the numbers of
struts (ns), inter-strut spacing (ISS), expansion diameter and level of strut embedment.
In total, 9 different geometrical configurations are simulated, as summarised in Table 2.
[Table 1 about here.]
[Table 2 about here.]
[Fig. 4 about here.]
3.2 Boundary conditions
The following boundary conditions were applied to the arterial wall mechanical model:
(a) at the lumen-arterial wall interface, Γet,i and Γet,d, a constant pressure of 100 mmHg
is used to simulate in vivo physiological conditions, (b) a displacement of 0.2 mm of the
stent struts domain, Ωs, against the wall is prescribed in order to achieve an extra dilata-
tion of the vessel that is usual in stenting techniques. For the biological species evolution,
flux and concentration continuity at the SES-media interface, Γiel, is prescribed. A zero
flux boundary condition, −n · (−Dj∇cj) = 0, where n is the unit normal vector to the
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corresponding exterior boundary and j denotes each layer of the arterial tissue, was ap-
plied at the following boundaries: lumen-wall interface, struts-wall interface, Γs, arterial
wall inlet, Γj,inlet, and outlet, Γj,outlet, and outer surface of the media, Γeel, in case of
GFs, MMPs, ECM and SMCs or SES-media interface in case of EC. All computational
boundaries and domains are shown in Fig. 4 for the baseline model.
3.3 Numerical methods
The commercial software package COMSOL Multiphysics 5.3 (COMSOL AB, Burling-
ton, MA, USA) was used to create the computational geometry and to solve numerically,
by means of the finite element method (FEM), the mechanobiological model detailed in
Section 2, which is composed of three coupled systems: (1) a steady system which simu-
lates the mechanical expansion of the stent used for the estimation of the level of damage
within the tissue, (2) a transient PDE system which simulates the temporal evolution of
the biological species in the arterial wall and, finally, (3) a stationary mechanical anal-
ysis to simulate the tissue growth that leads to restenosis. The computational domains
(stent struts, intima and media) were meshed using quadratic Lagrange triangular ele-
ments, resulting in an overall fine mesh with approximately 150.000 elements (Fig. 4b).
A mesh sensitivity analysis was carried out in order to investigate the model mesh inde-
pendence, testing a series of meshes with different mesh densities. Mesh independence
was obtained when there was less than 2% change in the mean concentration of the
biological species within the arterial wall for successive mesh refinements. The time-
advancing scheme used in the transient problem was a backward differentiation formula
(BDF) with variable order of accuracy varying from one to five and variable time step-
ping. Both stationary and transient problems were solved using a direct linear solver
(MUMPS) with relative and absolute tolerance assigned at 10-4 and 10-3, respectively.
3.4 Model parameters
Reference values of the parameters included in the governing equations are summarized
in Table 3. They correspond to the rates of production, degradation, proliferation and
differentiation, the diffusion coefficients of the biological species, the initial concentra-
tions and the threshold values taken into account. Wherever possible, the model input
parameters were derived directly from experimental data available in the literature, but
in some cases estimation was necessary to ensure that the evolution of the species was
broadly consistent with the time-course of restenosis described in some experimental
studies [2, 3, 5, 7].
[Table 3 about here.]
3.5 Sensitivity analysis
A sensitivity analysis of the 28 parameters indicated in Table 1 was performed in order
to evaluate the effect of varying each input parameter involved on the evolution of the
restenosis process and to test the robustness of the results of the computational model.
This is of particular importance because of the absence of a complete set of experimental
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data and the variability seen in many of the parameters. Computations were carried out
for four different values for each parameter apart from the reference value, RV, which is
shown in Table 3. The first two values were considered ± half the reference value of the
selected parameter and the other two were given by increasing and decreasing by one
order of magnitude, as can be seen in Table 4.
[Table 4 about here.]
4 Results and discussion
The cascade of events occurring within the arterial wall after the stenting procedure and
the consequent response of all the biological species are detailed in this section. The
level of damage, local concentrations of GFs, MMPs and ECM and local densities of the
SMCs and ECs have been evaluated over time at different points of the computational
domain, shown in Fig. 5a, in order to show the restenosis evolution and the stability of
the model. Points A and C are located close to a central stent strut in the media and
in the denuded SES between struts, respectively. Points B and D are situated far away
from the stented area in the media and SES, respectively. Moreover, in order to study
the evolution of the solute dynamics in the stented domain, where the behaviour of the
system will be more affected by the level of damage in the tissue, the distribution of all
the species at five different times of the simulation is shown.
4.1 Quantification of damage
The deformed baseline computational geometry is shown in Fig. 5a. The final radii after
deployment in the stented and unstented domain were 1.7 mm and 1.5 mm, respectively.
Moreover, the total wall thickness was reduced to approximately 0.4 mm in the stented
area. Fig. 5b displays the von Mises stress distribution in the arterial wall. The scaling of
the stress and the corresponding quantification of the initial damage has been performed
is detailed in subsection 3.2.
[Fig. 5 about here.]
4.2 Damage evolution for the baseline model
The local evolution of damage at points A and B is shown in Fig. 6a. At point B, the
level of damage is equal to zero at every time, demonstrating that the model does not
evolve over time in regions distant from the device. For this reason, local concentrations
of substances and local densities of cells at points located far away from the damage
caused by the stent remain approximately constant with time. At point A, the level of
damage in the tissue decays exponentially with time until the healing process is com-
plete. Fig. 6b shows the distribution of the damage in the stented domain over time.
Initially, the highest level of damage is found close to the stent struts and to the regions
between the struts, where the endothelium has been denuded. As time proceeds, dam-
age decreases continuously to zero in the radial and longitudinal directions towards the
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adventitial boundary and the unstented domain, respectively. The literature suggests that
wound healing is variable in duration. Comparing with our results it can be observed
that, from day 90, damage is essentially negligible across the entire baseline computa-
tional domain, indicating that the healing process is largely complete in agreement with
the classical healing response documented in Forrester et al. [2]. This healing process
is mainly governed by the evolution of the concentration of MMP as observed in Eq. 3
coupled with the remaining diffusion-reaction equations.
[Fig. 6 about here.]
4.3 Evolution of the species for the baseline model
The results for the GFs evolution are shown in Figs. 7a and 8a. At damaged vascular sites
(point A), the local concentration of growth factors initially increases abruptly peaking
approximately between 2 to 3 weeks after stent implantation. Following this peak, the
concentration decays exponentially over time returning to the physiological baseline
value, contributing to the stabilization of the synthetic SMCs, in agreement with the
temporal sequence of GFs expression documented in Forrester et al. [2]. As the GFs
production depends directly on damage (Eq. 4), at points far from the stented area (point
B), the concentration of GFs does not vary over time.
Figs. 7b and 8b show the evolution over time for the MMPs. At the beginning of the
simulation the initial concentration of MMP is set to a homeostatic value of 3.83·10-7
mol·m-3 [47]. The local concentration of MMP at point A starts increasing, mainly due to
its production by the synthetic SMCs, until reaching its maximum value at day 9, which
is consistent with the time course of expression of MMP-2 observed by Bendenck et
al. [59]. As MMP synthesis depends directly on the level of damage in the tissue, which
continues decreasing over time, the effect of the degradation term of Eq. 7 is greater
than the effect of the production term and, therefore, the concentration of MMPs starts
decreasing until reverting to its normal physiological levels [60].
The collagen variation over time is shown in Figs. 7c and 8c. At early times post-
deployment, the local concentration of ECM at point A is degraded as a consequence
of the increase of MMPs until reaching a minimum value of 4.02 mol·m-3 after 2 days.
From this point, its concentration starts increasing over time, mainly because of the
differentiation of the contractile SMCs and the proliferation of the synthetic SMCs, pro-
ducing neointimal thickening in the weeks after injury [7] until an equilibrium value of
approximately 7.8 mol·m-3 is reached at approximately day 50.
Figs. 7d, 8d and 7e, 8e illustrate the evolution of the contractile and synthetic SMCs,
respectively. At the beginning of the process, the local density of the contractile SMCs
at point A decreases due to the differentiation into a synthetic phenotype until reaching a
minimum value of 2.85·1013 cell·m-3 1-2 weeks after the stenting procedure. Meanwhile,
the synthetic SMCs are immediately activated and start proliferating in the media [3].
The local density of synthetic SMCs increases to a value of 3.92·1012 cell·m-3 between
2-3 weeks after injury [3], coinciding in time with the peak in the concentration of GFs
and demonstrating that locally produced GFs are a major stimulus for SMC migration
and proliferation, in agreement with Forrester et al. [2]. After this time, synthetic SMCs
begin to revert back to the contractile phenotype. This process continues over several
months and is paralleled by a change in the ECM [2]. It can be noted that the evolution
14
in the concentration of the ECM components, mainly collagen, play a key role in SMCs
differentiation, as discussed in subsection 3.3(a), since when the ECM concentration
is sufficiently low, synthetic SMCs appear, and when it is sufficiently high, contractile
SMCs appear.
Endothelial cells only exist within the intima and their behaviour is governed mainly by
proliferation and migration. The time-varying local density profiles of this cell type are
shown in Fig. 7f. It can be seen that at points where the endothelium has been denuded by
the stent (i.e. point C), ECs start proliferating at the beginning of the restenotic process.
Between days 100 to 150 they cease proliferation, reaching, at approximately day 180,
an equilibrium density of 5·1011 cell·m-3 [55] along the length of the SES, correspond-
ing to homeostatic conditions and in agreement with the temporal response described
by Forrester et al. [2]. It can be considered then that the endothelium has been com-
pletely restored. However, after this time restenotic events continue since both SMCs
proliferation/migration and ECM deposition does not necessarily cease at this time.
[Fig. 7 about here.]
[Fig. 8 about here.]
4.4 Sensitivity analysis
The results for the sensitivity analysis performed involving those parameters that have
shown to have a greater influence on the behaviour of the system are shown in Figs. 9
and 10. The discussion is included in the online Supplementary Material.
[Fig. 9 about here.]
[Fig. 10 about here.]
4.5 Tissue growth
The volumetric growth of new tissue into the lumen of the vessel in response to the
mechanical injury caused by the medical device after 300 days is shown in Fig. 11, for
the baseline model. It should be noticed that the restenotic tissue grows considerably
between struts. The degree of occlusion can be measured in terms of the diameter or
area of restenosis [61]. In this work, the change in the cross-sectional area of the model
is used as a measure of measuring arterial restenosis. The percentage of stenosis is cal-
culated as (1−Ar/Aref ) · 100, where Ar and Aref are the area of the lesion and of the
reference site, respectively. Therefore, the resulting degree of restenosis after 300 days
is approximately 25% for the baseline set of parameters simulated in broad agreement
with the clinical data presented in Nobuyoshi et al. [62].
[Fig. 11 about here.]
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4.6 Impact of geometric variations on tissue growth
In Figure 12, we consider the impact of different geometric configurations on the %
restenosis for the various cases considered in Table 2. The model produces different
levels of restenosis depending on the geometric parameters, and our results are in qual-
itative agreement with clinical observations. Specifically, the results of our simulations
show that % restenosis:
– increases with increasing strut diameter;
– decreases with an increase in inter-strut spacing;
– increases with an increase in lumen expansion diameter;
– depends on the strut embedment configuration.
[Fig. 12 about here.]
5 Limitations
We would like to emphasize that there are a number of limitations in this work, as we
now discuss.
5.1 Validation
Whilst the continuum approach that we have adopted is advantageous in that it allows
us to assess how the evolution of the various species affects the overall healing process,
the disadvantage is that it is extremely difficult to measure spatiotemporal cellular den-
sities and growth factor concentrations experimentally. Certainly, we are not aware of
how such validation may be obtained in vivo. In short, we do not believe that the data
currently exists to validate the predictions of the model at the level of individual concen-
trations/densities in space and in time. Therein lies the major advantage of the continuum
model proposed here, i.e. the ability to simulate the evolution of species which we can-
not get insight into from in vivo experiments. Notwithstanding, we have compared our
results to restenosis data (at the tissue level) and have shown that our model is in broad
agreement with what is seen in the clinic.
5.2 Flow modelling
We acknowledge that there is a known link between the level of shear stress and resteno-
sis. Indeed, most haemodynamics models that assess different stent designs and patient-
specific geometries set out to predict quantities such as wall shear stress (WSS), oscilla-
tory shear index (OSI) and time averaged wall shear stress (TAWSS), because these can
be related to clinical outcome. Keller et al. [63], for example, investigated the correlation
between mechanical and fluid stresses and the magnitude of restenosis, and found that
whilst a linear correlation is not obtained when these stimuli are considered separately,
there is a closer correlation when the combined action of these stimuli is considered.
Whilst such correlations are useful for providing insight into the influence of force on
restenosis, what is less clear, is precisely how the transmission of fluid forces affects
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the behaviour of the cells and other species involved in the healing response. The most
sophisticated model of restenosis to date (Zun et al. [29]) does include the effects of
flow, but in in an indirect way. Specifically, Zun et al. assume that neointimal growth is
dictated by nitric oxide (NO) production, which is governed by average WSS. There-
fore, Zun et al. calculate WSS from a steady laminar flow simulation and pass this to
their biological solver, where the level of NO dictates the ensuing biological response
through a set of rules. In the absence of data resolving the underlying physics of how the
transmission of force generated by flow affects the healing process in vivo, the influence
of flow has been neglected in the present analysis. Certainly, the force generated by flow
would influence the parameters of our model: in this sense, the sensitivity analysis could
be seen to indirectly incorporate the effects of varying flow.
5.3 Geometry
Concerning the geometry of the FE model, a 2D axisymmetric geometry corresponding
to an idealized representation of a straight segment of a healthy coronary artery has been
considered in this study. This could be improved using more realistic geometries of the
artery, such us coronary arteries with curvature, bifurcations, presence of atherosclerotic
plaque or derived directly from 3D patient-specific geometries. However, such models
would considerably increase the cost of the numerical simulations and are left for future
work.
5.4 Damage modelling
In this work, following the approach presented by Zahedmanesh et al. [22], the mod-
elling of the initial damage in the tissue after stenting is considered in a very simple
way, which is based on the ultimate tensile stress-stretch response for each layer of hu-
man coronary arteries [42]. However, to our knowledge, there is no experimental data
published in the literature which directly relates the levels of stress-strain due to stent
deployment to the arterial wall injury and the sequence of events associated such as GFs
and MMPs production, synthesis, number of proliferating SMCs, etc.
5.5 Model parameters and biological species
The biological parameters involved in this model were obtained from a wide range of
in vivo and in vitro experiments from the published literature on different blood vessels
from human and animal models. However, due to the important structural and functional
differences between arteries [48], these parameters could vary from artery-to-artery,
species-to-species and patient-to-patient, or even from one lesion to another in the same
patient. Additionally, some of these parameters have had to be estimated to be consis-
tent with the time course of the restenosis process found in different studies [2–5, 7].
Moreover, all the parameters have been taken as constant and uniform through the
whole artery, but in fact they are very likely to change produced during the process.
Finally, only the most important biological species have been taken into account. Other
species involved in the coronary restenosis process such as platelets, monocytes, dif-
ferent classes of GFs (PDGF, EGF, IGF, TGF, FGF), mesenchymal cells, fibroblasts,
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collagen subtypes, proteoglycans, fibronectin, etc. have been grouped or omitted. More-
over, only the main biological processes have been considered in this model. Other pro-
cesses such as activation and migration of the mesenchymal stem cells, release of GFs
by fibroblasts or ECM synthesis by ECs were not included.
6 Conclusions
A mathematical and computational model which successfully captures the main char-
acteristics of the restenosis process after stent implantation in a healthy coronary artery
has been presented in this work. A continuum approach has been taken into account for
modelling the behaviour of the different biological species involved in ISR, resulting in
a PDE system of several coupled diffusion-reaction equations, solved numerically by
means of FEM. Mechanical damage, which is quantitatively estimated as a function of
the von Mises stress levels obtained in the arterial wall after a FE simulation of the stent
expansion, is considered as the stimulus needed to start the process.
Our results confirm that ISR depends on multiple factors, with the ECM dynamics and
SMCs proliferation the primary contributors to its pathogenesis. In addition to this, the
sensitivity analysis carried out for the different model parameters, as well as providing
information on the stability of the model, provides us with an understanding of how
changes in one parameter will affect the behaviour of the whole system. The value of
kdeg,d has a significant impact on the healing rate. Moreover, it was shown that the rates
of production, degradation, differentiation and proliferation taken into account highly
affect the local levels of concentration/density of the species involved in the process and
the temporal response of the system. The apoptosis rate of synthetic SMCs, diffusion
coefficients and initial conditions also influence the evolution of the model, although to
a lesser extent.
In conclusion, in spite of the simplifications and limitations we have discussed, the
model developed is able to capture some of the underlying mechanisms and patterns
of ISR. Moreover, the results obtained are in good agreement with clinical hypotheses
relating to ISR occurrence. Therefore, this model can be considered as a step forward to
a better understanding of this phenomenon.
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TABLES 21
Parameter Description Value Reference
rl Lumen initial radius 1.2 mm [64]
δses Intima thickness 0.01 mm [19]
δm Media thickness 0.5 mm [17]
rs Strut radius 0.125 mm [16]
ws Interstrut distance 0.7 mm [16]
Table 1: List of parameters related to the geometry of the baseline model.
22 TABLES
Case Stent model Strut shape Strut size (µm) ISS (mm) ns Emb. config. Ratio
0 Baseline model circular 250 0.7 10 50% 1.1
1 Resolute (Medtronic) circular 91 0.7 10 50% 1.1
2 Xience (Abbott) square 81 0.7 10 50% 1.1
3 Biomatrix (Biosensors) square 120 0.7 10 50% 1.1
4 Baseline model circular 250 1.4 5 50% 1.1
5 Baseline model circular 250 1.0 7 50% 1.1
6 Baseline model circular 250 0.5 14 50% 1.1
7 Baseline model circular 250 0.7 10 25-75% 1.1
8 Baseline model circular 250 0.7 10 50% 1.2
Table 2: List of cases simulated to relate our findings to stent design. The last colum
refers to the ratio of the lumen diameter after stent expansion to the lumen diameter
before stent expansion.
TABLES 23
Parameter Description Value Reference
Rates
kdeg,d Damage degradation 0.5 m3·mol-1·s-1 Estimated
kprod,gf GF production 8·10-13 mol·m-3·s-1 Estimated
kdeg,gf GF degradation 1.27·10-6 s-1 [24]- [65]
kprod1,mmp MMP production by cSMC 3·10-26 mol·cell-1·s-1 Adapted from [22]
kprod2,mmp MMP production by sSMC 6·10-26 mol·cell-1·s-1 Adapted from [22]
kdeg,mmp MMP degradation 4.63·10-6 s-1 [24]
kprod,ecm ECM production by sSMC 2.157·10-11 g·cell-1·s-1 [36]
kdeg,ecm ECM degradation 2·103 s-1 Estimated
kdiff,csmc cSMC differentiation 5·10-7 s-1 [23]- [36]
kdiff,ssmc sSMC differentiation 2.314·10-6 s-1 [23]
kprolif,ssmc sSMC proliferation by GF 2.5·1013 cell·mol-1·s-1 Estimated
kapop,ssmc sSMC apoptosis 2.2·10-10 s-1 [66]
kprolif,ec EC proliferation 10-6 s-1 Adapted from [67]
Diffusion coefficients
Dgf Growth Factors 2.6·10-11 m2·s-1 [32]
Dmmp Matrix Metalloproteinases 1.2·10-12 m2·s-1 [68]
Decm Extracellular Matrix Neglected [36]
Dcsmc Contractile Smooth Muscle Cells Neglected [36]
Dssmc Synthetic Smooth Muscle Cells 1.85·10-13 m2·s-1 [69]
Dec Endothelial Cells 8·10-14 m2·s-1 [32]
Initial concentrations
cgf,0 GF initial concentration 3.48·10-7 mol·m-3 [44]
cmmp,0 MMP initial concentration 3.83·10-7 mol·m-3 [47]
cecm,0 ECM initial concentration 6.67 mol·m-3 [47]
ccsmc,0 cSMC initial concentration 3.16·1013 cell·m-3 [50]
cssmc,0 sSMC initial concentration 0 cell·m-3 [38]
cec,0 EC initial concentration 5·1011 cell·m-3 [55]
Threshold values
cgf,th GF threshold concentration 10 · cgf,0 Estimated
cmmp,th MMP threshold concentration 10 · cmmp,0 Estimated
cecm,th ECM threshold cecm,0 [38]
cecm,th1 ECM superior threshold 1.5 · cecm,0 Estimated
cecm,th2 ECM inferior threshold 0.1 · cecm,0 Estimated
Growthmodel
rec Endothelial cell radius 17.87 µm [22]
rsmc SMC radius 3.75 µm [57]
lsmc SMC length 115 µm [57]
ρecm ECM density 1 g·ml-1 [47]
Table 3: List of parameters related to the biological model.
24 TABLES
Case Parameter Unit RV/10 RV/2 RV 2RV 10 RV
01 kdeg,d m3·mol-1·s-1 0.05 0.25 0.5 1 5
02 kprod,gf mol·m-3·s-1 8·10-14 4·10-13 8·10-13 1.6·10-12 8·10-12
03 kdeg,gf s-1 1.27·10-7 6.35·10-7 1.27·10-6 2.54·10-6 1.27·10-5
04 kprod1,mmp mol·cell-1·s-1 3·10-27 1.5·10-26 3·10-26 6·10-26 3·10-25
05 kprod2,mmp mol·cell-1·s-1 6·10-27 3·10-26 6·10-26 1.2·10-25 6·10-25
06 kdeg,mmp s-1 4.63·10-7 2.31·10-6 4.63·10-6 9.26·10-6 4.63·10-5
07 kprod,ecm g·cell-1·s-1 2.15·10-12 1.07·10-11 2.15·10-11 4.31·10-11 2.15·10-10
08 kdeg,ecm s-1 2·102 1·103 2·103 4·103 2·104
09 kdiff,csmc s-1 5·10-8 2.5·10-7 5·10-7 ·10-6 5·10-6
10 kdiff,ssmc s-1 2.31·10-7 1.15·10-6 2.31·10-6 4.62·10-6 2.31·10-5
11 kprolif,ssmc cell·mol-1·s-1 2.5·1012 1.25·1013 2.5·1013 5·1013 2.5·1014
12 kapop,ssmc s-1 2.2·10-11 1.1·10-10 2.2·10-10 4.4·10-10 2.2·10-9
13 kprolif,ec s-1 10-7 5·10-7 10-6 2·10-6 10-5
14 Dgf m2·s-1 2.6·10-12 1.3·10-11 2.6·10-11 5.2·10-11 2.6·10-10
15 Dmmp m2·s-1 1.2·10-13 6·10-13 1.2·10-12 2.4·10-12 1.2·10-11
16 Dssmc m2·s-1 1.85·10-14 9.26·10-13 1.85·10-13 3.7·10-13 1.85·10-12
17 Dec m2·s-1 8·10-15 4·10-14 8·10-14 1.6·10-13 8·10-13
18 cgf,0 mol·m-3 3.48·10-8 1.74·10-7 3.48·10-7 6.96·10-7 3.48·10-6
19 cmmp,0 mol·m-3 3.83·10-8 1.91·10-7 3.83·10-7 7.66·10-7 3.83·10-6
20 cecm,0 mol·m-3 0.667 3.335 6.67 13.33 66.7
21 ccsmc,0 cell·m-3 3.16·1012 1.58·1013 3.16·1013 6.32·1013 3.16·1014
22* cssmc,0 cell·m-3 0 (RV) 3.16·1012 1.58·1013 3.16·1013 -
23 cec,0 cell·m-3 5·1010 2.5·1011 5·1011 1·1012 5·1012
24 cgf,th mol·m-3 3.48·10-7 1.74·10-6 3.48·10-6 6.96·10-6 3.48·10-5
25 cmmp,th mol·m-3 3.83·10-7 1.91·10-6 3.83·10-6 7.66·10-6 3.83·10-5
26 cecm,th mol·m-3 0.667 3.335 6.67 13.33 66.7
27 cecm,th1 mol·m-3 1 5 10 20 100
28 cecm,th2 mol·m-3 0.067 0.333 0.667 1.333 6.67
Table 4: List of cases with the corresponding parameter values computed in the
sensitivity analysis. (*) Note that due to the reference value of cssmc,0 in case 22, being
equal to zero, the strategy for varying parameters had to be adjusted. Points A and C
are located close to a central stent strut in the media and in the denuded SES between
struts, respectively. Points B and D are situated far away from the stented area in the
media and SES, respectively.
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Fig. 1: Schematic representation of ISR. In summary, prior to stent deployment, SMCs exist in
a quiescent and contractile phenotype predominantly in the media layer of the tissue and ECs
populate the uninjured arterial wall (a). After stent deployment (b), endothelial denudation,
atherosclerotic plaque compression (often with dissection into the media and occasionally
adventitia), and unphysiological stretch of the entire artery occur [7]. Platelets are then
deposited at the injured area and GFs are released. Local increases in stationary mechanical
strain, which occurs following stenting, lead to up-regulation of MMP by SMCs and
degradation of collagen in the ECM. Endothelial damage and denudation, among multiple
factors, lead to the phenotype switch of medial SMCs from a contractile to a synthetic state [3].
Synthetic SMCs proliferate in response to GFs [24] first in the media and then these begin to
migrate towards the injured area (c, d). Simultaneously, ECs migrate from the lateral edge of
the damaged blood vessel surface [2] (e). Moreover, synthetic SMCs secrete ECM components,
such as collagen and proteoglycans, which constitute the neointimal lesion [24]. Between 2-3
weeks after the stenting procedure, synthetic SMCs begin to revert to the contractile
phenotype [2]. Neointima typically increases up to three months after the procedure, with little
change to six months and a gradual reduction between six months to three years [6] (e, f).
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Fig. 2: Initial damage as a function of von Mises stress in the arterial wall. In this
work, the value selected for the inferior limit of the von Mises stress is 165 kPa,
corresponding to three times the value of the physiological circumferential tension
calculated by Laplace’s law, for a given blood pressure of 100 mmHg (13.3 kPa). For
the superior limit of the von Mises stress, a value of 446 kPa was chosen, based on the
mean value of the ultimate tensile stresses (UTS) for the media layer in the
circumferential direction reported by Holzapfel et al. [42].
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Fig. 3: Behaviour of the switch functions defined by Eqs. (8) and (9).
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Fig. 4: (a) Baseline model geometry. The arterial wall is modeled as a multilayer structure
distinguishing two different domains: intima and media layer. The adventitia is not modeled as
a distinct layer but rather as a boundary condition at the outer surface of the media. The initial
luminal radius, rl, and the thickness of each wall layer, δj , in the unloaded geometry of the
vessel are listed in Table 1, based on typical physiological values found in the literature. The
stent implanted in the arterial wall is represented by 10 circular struts each of 0.125 mm radius,
rs, half-embedded in the tissue and located 0.7 mm centre-to-centre distance, ws, simulating a
small lesion of 7 mm. We note that the problem is actually symmetrical about the r-axis, i.e.
half way between the 5th and 6th struts. (b) Details of the finite element (FE) mesh of the
computational model.
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Fig. 5: (a) Deformed computational geometry and (b) von Mises stress distribution and
corresponding quatification of the initial damage in the arterial wall. Points A and C are located
close to a central stent strut in the media and in the denuded SES between struts, respectively.
Points B and D are situated far away from the stented area in the media and SES, respectively.
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Fig. 6: Local evolution of the damage over time at two different points within the media (a) and
distribution of damage in the stented area of the arterial wall at five different times after stent
implantation (b). Point A and point B are located close to a central stent strut and far away
from the effect of the stent in the media, respectively.
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Fig. 7: Time-varying local concentration/density profiles of (a) GFs, (b) MMPs, (c) ECM, (d)
contractile SMCs, (e) synthetic SMCs and (f) ECs at two different points within the arterial
wall. Points A and C are located close to a central stent strut in the media and in the denuded
SES between struts, respectively. Points B and D are situated far away from the stented area in
the media and SES, respectively.
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Fig. 8: Evolution of the distribution of all biological species in the media layer of the arterial
wall at different times of the simulation. The substances concentration and cells density are
shown in mol·m-3 and cell·m-3, respectively.
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Fig. 9: Influence of varying damage degradation rate on the evolution of the damage. Please
refer to the online Supplementary Material for a discussion.
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Fig. 10: Key results from the sensitivity analysis. The plots show the effect of varying several
parameters on the concentration of GFs, MMPs and ECM as well as the density of contractile
and synthetic SMCs for 8 different cases. Computations were carried out for four different
values for each parameter apart from the reference value, RV, which is shown in Table 3. The
values of 2RV and RV/2 were considered ± half the RV of the selected parameter; 10RV and
RV/10 were given by increasing and decreasing by one order of magnitude the RV (see Table
4). The results shown for point B correspond exclusively to the RV (baseline model). Please
refer to the online Supplementary Material for a discussion.
FIGURES 35
Fig. 11: Evolution of the volumetric growth at different times of the simulation for the baseline
model.
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Fig. 12: The impact of different geometric configurations (Table 2) on Von Mises stress
distribution and volumetric growth after 300 days.
